Lifecare ASA — Director's Dealing 2026

Mar 6, 2026

Lifecare ASA: Mandatory notification of trade

Lifecare ASA: Mandatory notification of trade

Reference is made to the stock exchange announcement by Lifecare ASA (the

"Company") on 2 March 2026 regarding the commencement of the exercise period

for Warrants Series 1 issued in connection with the partially underwritten

rights issue completed in January 2026. Each Warrant Series 1 entitles the

holder to subscribe for one new share in the Company at an exercise price of

NOK 0.3342 per share.

The exercise period for Warrants Series 1 commenced on 2 March 2026 and

expires at 16:30 (CET) on 13 March 2026 (the "Exercise Period").

Warrants Series 1 are listed and tradable on Euronext Oslo Børs under the

ticker code "LIFEJ". Trading in Warrants Series 1 will be halted five trading

days prior to the expiry of the Exercise Period in order to facilitate

settlement of exercised warrants. Consequently, Warrants Series 1 will be

tradable up to and including today 6 March 2026 at 16:30 (CET).

Warrants Series 1 not sold on or before today at 16:30 (CET) or not exercised

on or before 13 March 2026 at 16:30 (CET) will lapse without compensation.

Holders of Warrants Series 1 who do not exercise their warrants may experience

dilution of their shareholding in the Company.

The Company has been informed that Joacim Holter, CEO and primary insider of

the Company, has purchased 600,000 Warrants Series 1 at an average price of

NOK 0.0142 per warrant.

Following this transaction, Joacim Holter holds 104,256 shares and 600,000

Warrants Series 1 in the Company.

Please see the attached notification form for further details.

This information is subject to the disclosure requirements pursuant to Article

19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian

Securities Trading Act.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring systems to market. Lifecare

enables osmotic pressure as sensing principle. Lifecare's sensor technology is

suitable for identifying and monitoring the occurrence of a wide range of

analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR Article 17. The information was submitted for publication,

through the agency of the contact persons set out above, at 2026-03-06 09:01

CET.